CN108997300B - 7, 8-difluoro-1, 3-dihydroxy xanthone and preparation method and application thereof - Google Patents
7, 8-difluoro-1, 3-dihydroxy xanthone and preparation method and application thereof Download PDFInfo
- Publication number
- CN108997300B CN108997300B CN201810795882.3A CN201810795882A CN108997300B CN 108997300 B CN108997300 B CN 108997300B CN 201810795882 A CN201810795882 A CN 201810795882A CN 108997300 B CN108997300 B CN 108997300B
- Authority
- CN
- China
- Prior art keywords
- difluoro
- preparation
- dihydroxy xanthone
- xanthone
- dihydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 7
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 5
- VOMFCQHTOYKKFT-UHFFFAOYSA-N 1,2-difluoro-6,8-dihydroxyxanthen-9-one Chemical compound FC1=CC=C2OC=3C=C(C=C(C=3C(C2=C1F)=O)O)O VOMFCQHTOYKKFT-UHFFFAOYSA-N 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 abstract description 16
- 201000007270 liver cancer Diseases 0.000 abstract description 15
- 239000002246 antineoplastic agent Substances 0.000 abstract description 5
- 206010006187 Breast cancer Diseases 0.000 abstract description 4
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 4
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 208000032839 leukemia Diseases 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 12
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 7
- XQQZVFHVBKZXBK-UHFFFAOYSA-N 2,3-difluoro-6-hydroxybenzoic acid Chemical compound OC(=O)C1=C(O)C=CC(F)=C1F XQQZVFHVBKZXBK-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- JPYHHZQJCSQRJY-UHFFFAOYSA-N Phloroglucinol Natural products CCC=CCC=CCC=CCC=CCCCCC(=O)C1=C(O)C=C(O)C=C1O JPYHHZQJCSQRJY-UHFFFAOYSA-N 0.000 description 6
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 description 6
- 229960001553 phloroglucinol Drugs 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 229940098779 methanesulfonic acid Drugs 0.000 description 5
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- -1 7, 8-difluoro-1, 3-dihydroxyxanthone compound Chemical class 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 150000007964 xanthones Chemical class 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 229910006069 SO3H Inorganic materials 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000012295 chemical reaction liquid Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- JNELGWHKGNBSMD-UHFFFAOYSA-N xanthone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3OC2=C1 JNELGWHKGNBSMD-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- GTHOERCJZSJGHB-UHFFFAOYSA-N 3-dihydroxyxanthone Natural products C1=CC=C2C(=O)C3=C(O)C=C(O)C=C3OC2=C1 GTHOERCJZSJGHB-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UZUODNWWWUQRIR-UHFFFAOYSA-L disodium;3-aminonaphthalene-1,5-disulfonate Chemical compound [Na+].[Na+].C1=CC=C(S([O-])(=O)=O)C2=CC(N)=CC(S([O-])(=O)=O)=C21 UZUODNWWWUQRIR-UHFFFAOYSA-L 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- AJDUTMFFZHIJEM-UHFFFAOYSA-N n-(9,10-dioxoanthracen-1-yl)-4-[4-[[4-[4-[(9,10-dioxoanthracen-1-yl)carbamoyl]phenyl]phenyl]diazenyl]phenyl]benzamide Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2NC(=O)C(C=C1)=CC=C1C(C=C1)=CC=C1N=NC(C=C1)=CC=C1C(C=C1)=CC=C1C(=O)NC1=CC=CC2=C1C(=O)C1=CC=CC=C1C2=O AJDUTMFFZHIJEM-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000001043 yellow dye Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
- C07D311/82—Xanthenes
- C07D311/84—Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
- C07D311/86—Oxygen atoms, e.g. xanthones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The inventor provides a novel fluoro-1, 3-dihydroxy xanthone compound 7, 8-difluoro-1, 3-dihydroxy xanthone, a preparation method thereof and application thereof in antitumor drugs, in particular in the preparation of drugs for leukemia, liver cancer, breast cancer and colon cancer.
Description
Technical Field
The invention relates to the field of medical chemistry, in particular to 7, 8-difluoro-1, 3-dihydroxy xanthone, a preparation method and application thereof.
Background
Xanthones, also known as xanthones, are the first secondary metabolites isolated from some plants and microorganisms, and contain the parent structure of dibenzo-gamma-pyrones. Xanthone compounds with different structures often have different pharmacological actions or activity degrees. Changes in one or more substituents of the xanthone parent ring can affect its biological activity. The xanthones which have been found to date have a number of important biological activities. Such as antihypertensive, antibacterial, antithrombotic, antitumor, and obesity-suppressing activities.
On the basis of natural medicines, the synthesis of new compounds by chemical means is an important direction for the development of new medicines at present.
Disclosure of Invention
The invention provides a novel fluoro-1, 3-dihydroxy xanthone compound 7, 8-difluoro-1, 3-dihydroxy xanthone, a preparation method and application thereof, wherein the structure of the compound is shown as (I):
the present inventors also provide a method for preparing 7, 8-difluoro-1, 3-dihydroxyxanthone, comprising a process of reacting 5, 6-difluoro-2-hydroxybenzoic acid, phloroglucinol, phosphorus pentoxide, and methanesulfonic acid.
Further, the molar ratio of 5, 6-difluoro-2-hydroxybenzoic acid to phloroglucinol is 4-5: 4-5.
Further, the method comprises the following steps:
preparing a mixed solution: dissolving phosphorus pentoxide in methanesulfonic acid to prepare a mixed solution; the dissolving temperature is controlled at 105-115 ℃;
and (3) cyclization reaction: adding 5, 6-difluoro-2-hydroxybenzoic acid and phloroglucinol into the mixed solution to carry out cyclization reaction to generate 7, 8-difluoro-1, 3-dihydroxy xanthone, wherein the reaction temperature is controlled at 88-92 ℃, and the reaction time is controlled at 18-22 min;
solid-liquid separation and purification: and (3) precipitating, filtering and carrying out column chromatography separation on the solution containing the 7, 8-difluoro-1, 3-dihydroxy xanthone after the cyclization reaction is finished to obtain a finished product of the 7, 8-difluoro-1, 3-dihydroxy xanthone.
The inventor further provides application of the 7, 8-difluoro-1, 3-dihydroxy xanthone in preparing antitumor drugs.
Further, the tumor comprises: hematopoietic stem cell tumor, liver cell tumor, lung cell tumor, breast cell tumor, colon cell tumor.
The present inventors also provide an antitumor agent containing a 7, 8-difluoro-1, 3-dihydroxyxanthone compound or a pharmaceutically acceptable salt or ester thereof as an active ingredient.
The present inventors also provide an antitumor pharmaceutical composition containing a 7, 8-difluoro-1, 3-dihydroxyxanthone compound or a pharmaceutically acceptable salt or ester thereof as an active ingredient.
Further, the medicine or the medicine composition comprises tablets, capsules, pills, injections, sustained-release preparations and various microparticle administration systems.
Different from the prior art, the technical scheme provides a novel fluoro 1, 3-dihydroxy xanthone compound, a preparation method thereof and application thereof in antitumor drugs, in particular to drug preparation in leukemia, lung cancer, liver cancer, breast cancer and colon cancer.
Detailed Description
In order to explain technical contents, structural features, and objects and effects of the technical means in detail, the following detailed description is given with reference to specific embodiments.
In this embodiment, 7, 8-difluoro-1, 3-dihydroxyxanthone:
example 1: synthesis of 7, 8-difluoro-1, 3-dihydroxyxanthone
Phosphorus pentoxide (0.68g, 4.8mmol) and 15mL methanesulfonic acid (CH)3SO3H) The mixture was successively charged into a 50mL round-bottomed flask, heated to 110 ℃ and stirred to dissolve the mixture, and then the reaction mixture was cooled to 90 ℃ and 5, 6-difluoro-2-hydroxybenzoic acid (1.6mmol) and phloroglucinol (0.20g, 1.6mmol) were added and reacted at 90 ℃ for about 20 min. Pouring the reaction liquid into water, separating out solid, carrying out suction filtration and natural drying, and enabling the primary product to pass through a 200-mesh and 300-mesh pressurized silica gel column by using a mixed solvent of ethyl acetate and petroleum ether to obtain the 7, 8-difluoro-1, 3-dihydroxy xanthone which is a white-like solid with the yield of 48%.
The infrared spectrum data are as follows: IR (KBr) vmax 661,800,1178,1296,1511,1617,3426cm-1;1H NMR(500MHz,CD3SOCD3)δ6.21(d,1H,J=2.1Hz,H-2),6.37(d,1H,J=2.1Hz,H-4),7.87(dd,1H,J=6.5,10.5Hz,H-5),8.03(t,1H,J=10.5Hz,H-6),11.8(s,OH-3),12.51(s,OH-1);13C NMR(125MHz,CD3SOCD3)δ94.2,98.6,101.8,106.5,107.5,112.6,117.0,145.9,152.2,157.5,162.7,166.1,178.3;HR-ESI-MS:m/z 263.0160[M-H]-(calcd for C13H5F2O4,263.0161).
The 7, 8-difluoro-1, 3-dihydroxyxanthone can be synthesized according to the following procedures:
example Synthesis of 27, 8-difluoro-1, 3-dihydroxyxanthone
Phosphorus pentoxide (5mmol) and 15mL of methanesulfonic acid (CH)3SO3H) Sequentially adding into a 50mL round-bottom flask, heating to 105 deg.C, stirring to dissolve, cooling the reaction solution to 88 deg.C, adding 5, 6-difluoro-2-hydroxybenzoic acid (1.6mmol) and phloroglucinol (2.0mmol), and reacting at 88 deg.C for 18 min. Pouring the reaction liquid into water, separating out solid, carrying out suction filtration and natural drying, and enabling the primary product to pass through a 200-mesh and 300-mesh pressurized silica gel column by using a mixed solvent of ethyl acetate and petroleum ether to obtain the 7, 8-difluoro-1, 3-dihydroxy xanthone which is a white-like solid.
Example Synthesis of 37, 8-difluoro-1, 3-dihydroxyxanthone
Phosphorus pentoxide (4.5mmol) and 15mL of methanesulfonic acid (CH)3SO3H) Sequentially adding into a 50mL round-bottom flask, heating to 115 deg.C, stirring to dissolve, cooling the reaction solution to 92 deg.C, adding 5, 6-difluoro-2-hydroxybenzoic acid (2.0mmol) and phloroglucinol (1.6mmol), and reacting at 92 deg.C for 22 min. Pouring the reaction liquid into water, separating out solid, carrying out suction filtration and natural drying, and enabling the primary product to pass through a 200-mesh and 300-mesh pressurized silica gel column by using a mixed solvent of ethyl acetate and petroleum ether to obtain the 7, 8-difluoro-1, 3-dihydroxy xanthone which is a white-like solid.
Example 4: antitumor Activity test of 7, 8-difluoro-1, 3-dihydroxyxanthone
(1) The MTS method is used for detecting the cell activity principle: MTS is a novel MTT analogue, known as 3- (4, 5-dimethylthiozol-2-yl) -5 (3-carboxymethyloxyphenyl) -2- (4-sulfop heny) -2H-tetrazolium, and is a yellow dye. Succinate dehydrogenase in the mitochondria of living cells can metabolize and reduce MTS to generate soluble Formazan (Formazan) compounds, and the content of the Formazan can be measured at 490nm by using an enzyme labeling instrument. Since the formazan production amount is generally proportional to the number of living cells, the number of living cells can be estimated from the optical density OD value.
(2) Experimental methods
Inoculating cells: preparing single cell suspension by using culture solution (DMEM or RMPI1640) containing 10% fetal bovine serum, inoculating 3000-15000 cells in each well into a 96-well plate, wherein each well volume is 100 mu l, and the adherent cells are inoculated and cultured 12-24h in advance.
Adding a solution of a compound to be detected: compounds were dissolved in DMSO and compounds were prescreened at a concentration of 40. mu.M, with a final volume of 200. mu.l per well, with 3 replicates per treatment.
③ developing color: after culturing for 48h at 37 ℃, removing culture solution in each hole of the adherent cells, and adding 20 mul of MTS solution and 100 mul of culture solution into each hole; discarding 100 mul of culture supernatant from the suspension cells, and adding 20 mul of MTS solution into each well; 3 blank double wells (mixed solution of 20. mu.l MTS solution and 100. mu.l culture medium) were set, and incubation was continued for 2-4 hours to allow the reaction to proceed sufficiently, and then the light absorption value was measured.
And fourthly, color comparison: selecting 492nm wavelength, reading the light absorption value of each hole by a multifunctional microplate reader (MULTISKAN FC), recording the result, and drawing a tumor cell inhibition rate graph by taking the compound number as the abscissa and the cell inhibition rate as the ordinate after data processing.
The human tumor and normal cells detected are as follows: leukemia HL-60, lung cancer A-549, liver cancer SMMC-7721, breast cancer MCF-7, colon cancer SW480, liver cancer Huh-7, liver cancer HepG2, liver cancer MHCC97H, liver cancer PLC/PRF/5, liver cancer SK-HEP-1 and human normal liver cell HL-7702.
Sixthly, for the tumor cells with the inhibition rate of more than 50 percent, determining the IC of the compound on the tumor cells50The value is obtained. Two positive compounds of cisplatin (DDP) and paclitaxel (Taxol) are set in each experiment, a cell growth curve is drawn by taking the concentration as the abscissa and the cell survival rate as the ordinate, and the IC of the compound is calculated by using a two-point method (Reed and Muench method)50The value is obtained.
Using cisplatin (DDP) and paclitaxel (Taxol) as positive control compounds, a small amount of 7, 8-difluoro-1, 3-dihydroxyxanthone synthesized in example 1 was dissolved in DMSO to prepare a 40. mu.M solution according to the MTS method, and then the inhibitory activity of the tumor cells was examined (tables 1 to 3).
Inhibitory Activity of the Compounds of Table 1 against 5 tumor cells
Table 1 The inhibitory activities of compound against five tumor cells
TABLE 2 inhibitory Activity of the Compounds on 6 other hepatocytes
Table 2 The inhibitory activities of compound against the other six liver cells
IC of Table 3 Compounds on liver cancer SMMC-7721 cells50Value of
Table 3 The IC50values ofthe compound against liver tumor SMMC-7721 cells
From tables 1-2, it can be derived: the inhibition rate of 40 mu M of 7, 8-difluoro-1, 3-dihydroxy xanthone on leukemia HL-60, lung cancer A-549, breast cancer MCF-7, colon cancer SW480, liver cancer Huh-7, liver cancer HepG2, liver cancer PLC/PRF/5 and liver cancer SK-HEP-1 is 10-45%. Thus, 7, 8-difluoro-1, 3-dihydroxyxanthone has some degree of inhibitory activity on these cells.
It can also be derived from tables 1-3: the inhibition rate of 40 μ M7, 8-difluoro-1, 3-dihydroxy xanthone on human liver cancer SMMC-7721 is 50.96 + -0.54%, corresponding IC50The value was 32.40. + -. 0.74. mu.M. Therefore, the 7, 8-difluoro-1, 3-dihydroxy xanthone has better inhibitory activity on human liver cancer SMMC-7721.
The 7, 8-difluoro-1, 3-dihydroxy xanthone is a new compound, the synthesis and the biological activity of which are not reported in documents or patents, and can be used for preparing antitumor drugs.
It is noted that, herein, relational terms such as first and second, and the like may be used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Also, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or terminal that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or terminal. Without further limitation, an element defined by the phrases "comprising … …" or "comprising … …" does not exclude the presence of additional elements in a process, method, article, or terminal that comprises the element. Further, herein, "greater than," "less than," "more than," and the like are understood to exclude the present numbers; the terms "above", "below", "within" and the like are to be understood as including the number.
It should be noted that, although the above embodiments have been described herein, the invention is not limited thereto. Therefore, based on the innovative concepts of the present invention, the technical solutions of the present invention can be directly or indirectly applied to other related technical fields by making changes and modifications to the embodiments described herein or by using equivalent structures or equivalent processes performed in the present specification, and are included in the scope of the present invention.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810795882.3A CN108997300B (en) | 2018-07-19 | 2018-07-19 | 7, 8-difluoro-1, 3-dihydroxy xanthone and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810795882.3A CN108997300B (en) | 2018-07-19 | 2018-07-19 | 7, 8-difluoro-1, 3-dihydroxy xanthone and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108997300A CN108997300A (en) | 2018-12-14 |
CN108997300B true CN108997300B (en) | 2021-09-03 |
Family
ID=64596729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810795882.3A Expired - Fee Related CN108997300B (en) | 2018-07-19 | 2018-07-19 | 7, 8-difluoro-1, 3-dihydroxy xanthone and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108997300B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107698550A (en) * | 2017-09-26 | 2018-02-16 | 莆田学院 | A kind of xanthone compound of 2,4 difluorophenyl substitution and its preparation method and application |
CN107759558A (en) * | 2017-09-26 | 2018-03-06 | 莆田学院 | A kind of xanthone compound of trifluoromethyl substitution and its preparation method and application |
-
2018
- 2018-07-19 CN CN201810795882.3A patent/CN108997300B/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107698550A (en) * | 2017-09-26 | 2018-02-16 | 莆田学院 | A kind of xanthone compound of 2,4 difluorophenyl substitution and its preparation method and application |
CN107759558A (en) * | 2017-09-26 | 2018-03-06 | 莆田学院 | A kind of xanthone compound of trifluoromethyl substitution and its preparation method and application |
Non-Patent Citations (1)
Title |
---|
Synthesis and antitumor, antityrosinase, and antioxidant activities of xanthone;B.-D. ZHOU. et al;《Journal of Asian Natural Products Research》;20180330;第20卷(第5期);第467-476页 * |
Also Published As
Publication number | Publication date |
---|---|
CN108997300A (en) | 2018-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107759558B (en) | Trifluoromethyl substituted xanthone compound and preparation method and application thereof | |
CN107674083A (en) | A kind of preparation method and applications of the L leucine ring substituent norcantharidin derivatives of the structure containing pyridazinone | |
CN107698550A (en) | A kind of xanthone compound of 2,4 difluorophenyl substitution and its preparation method and application | |
CN109776556B (en) | Pyrazolone xanthone skeleton spliced oxindole or benzofuranone compound and preparation method and application thereof | |
CN108299398B (en) | Carbazole-containing quinazoline derivative with anti-tumor activity and pharmaceutical application thereof | |
CN108299330B (en) | Dehydroabietic acid oxazolidinone derivative and preparation method and application thereof | |
CN107286220B (en) | 1,2, 4-triazole coupled dihydromyricetin derivative and preparation method and application thereof | |
CN108997300B (en) | 7, 8-difluoro-1, 3-dihydroxy xanthone and preparation method and application thereof | |
CN108752306B (en) | 6-fluoro-1, 3-dihydroxy xanthone and preparation method and application thereof | |
CN107043345A (en) | Preparation, structure and the purposes of the diketone Schiff base of 4-acetylbiphenyl hydrazone indoline 2,3 | |
CN111333495B (en) | (4-methoxy-3-hydroxyphenyl) (3, 5-dimethyl-2-hydroxyphenyl) ketone, and preparation method and application thereof | |
CN108689983B (en) | 5,7, 8-trichloro-1, 3-dihydroxy xanthone compound, preparation method and application | |
CN111196791B (en) | Chiral gamma-butyrolactone derivative and synthesis method and application thereof | |
CN106220642B (en) | A kind of L-Leu ring substituent norcantharidin derivative and the preparation method and application thereof | |
CN111004145B (en) | Chiral optical amide substituted alpha, beta-diamino acid derivative and preparation method and application thereof | |
CN106083873A (en) | A kind of L phenylalanine ring substituent norcantharidin derivative and preparation method and application | |
CN106188080A (en) | A kind of D phenylalanine ring substituent norcantharidin derivative and preparation method and application | |
CN111892486B (en) | Hydroxyl-substituted benzophenone compound and preparation method and application thereof | |
CN106083884A (en) | A kind of D leucine ring substituent norcantharidin derivative and preparation method and application | |
CN111018820A (en) | Crystal form A of fisetin, and preparation method and application thereof | |
CN106188081B (en) | A kind of D-Val ring substituent norcantharidin derivative and the preparation method and application thereof | |
CN105837516B (en) | A kind of rosuvastain calcium crystal form and preparation method thereof | |
CN115028643B (en) | Pyranoquinoline derivative, preparation method and application thereof | |
CN113292573B (en) | Indolizine chromogen ketone compound with anti-tumor activity and preparation method and application thereof | |
CN111018780B (en) | N-carbonyl-9, 10-dihydroacridine compound and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210903 |